Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice

Stem Cells

Volumn 30, Issue 6, 2012, Pages 1064-1075

  Lee, Cathy ^a   Fotovati, Abbas ^a   Triscott, Joanna ^a   Chen, James ^a   Venugopal, Chitra ^b   Singhal, Ash ^c   Dunham, Christopher ^c   Kerr, John M ^c   Verreault, Maite ^d   Yip, Stephen ^e   Wakimoto, Hiroaki ^f   Jones, Chris ^g   Jayanthan, Aarthi ^h   Narendran, Aru ^h   Singh, Sheila K ^b   Dunn, Sandra E ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Apoptosis; Cancer; Cancer stem cells; Glioma

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; POLO LIKE KINASE 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN TUMOR; CANCER INHIBITION; CANCER MORTALITY; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL STRUCTURE; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NEURAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT FAILURE; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEURAL STEM CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; SOXB1 TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TRANSFECTION;

MUS;

EID: 84861854588     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1081     Document Type: Article

References (87)

1. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9: 157-173. (Pubitemid 43357943)
2. McKinney PA. Brain tumours: Incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry 2004;75(suppl 2):ii12-ii17.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737. (Pubitemid 27298715)
4. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
5. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
6. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
7. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
8. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5. (Pubitemid 44959518)
9. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
10. Hussein D, Punjaruk W, Storer LC et al. Pediatric brain tumor cancer stem cells: Cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro Oncol 2011;13:70-83.
11. Eramo A, Ricci-Vitiani L, Zeuner A et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13:1238-1241. (Pubitemid 43905604)
12. Faury D, Nantel A, Dunn SE et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-1208. (Pubitemid 46640565)
13. Gao Y, Fotovati A, Lee C et al. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 2009;8:3276-3284.
14. Fotovati A, Abu-Ali S, Wang PS et al. YB-1 bridges neural stem cells and brain-tumor initiating cells via its roles in differentiation and cell growth. Cancer Res 2011;71:5569-5578.
15. Hu K, Lee C, Qiu D et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009;8:3024-3035.
16. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-1713. (Pubitemid 27036434)
17. Rapley J, Baxter JE, Blot J et al. Coordinate regulation of the mother centriole component nlp by nek2 and plk1 protein kinases. Mol Cell Biol 2005;25:1309-1324. (Pubitemid 40204909)
18. Casenghi M, Barr FA, Nigg EA. Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome. J Cell Sci 2005;118:5101-5108. (Pubitemid 41672440)
19. van Vugt MA, van de Weerdt BC, Vader G et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279:36841-36854. (Pubitemid 39129033)
20. Sumara I, Gimenez-Abian JF, Gerlich D et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004; 14:1712-1722. (Pubitemid 39301160)
21. Feng Y, Yuan JH, Maloid SC et al. Polo-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation. Biochem Biophys Res Commun 2006;349:144-152. (Pubitemid 44331774)
22. Yarm FR. Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 2002;22:6209-6221. (Pubitemid 34857840)
23. Roshak AK, Capper EA, Imburgia C et al. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25c phosphatase. Cell Signal 2000;12:405-411. (Pubitemid 30417604)
24. Golan A, Yudkovsky Y, Hershko A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J Biol Chem 2002;277:15552-15557. (Pubitemid 34967823)
25. Moshe Y, Boulaire J, Pagano M et al. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci USA 2004;101:7937-7942. (Pubitemid 38698032)
26. Hansen DV, Loktev AV, Ban KH et al. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell 2004;15:5623-5634. (Pubitemid 39564753)
27. Seong YS, Kamijo K, Lee JS et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002;277:32282-32293. (Pubitemid 34969045)
28. Zhou T, Aumais JP, Liu X et al. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003;5:127-138. (Pubitemid 36827347)
29. Neef R, Preisinger C, Sutcliffe J et al. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J Cell Biol 2003;162:863-875. (Pubitemid 37087726)
30. Niiya F, Tatsumoto T, Lee KS et al. Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene 2006;25:827-837. (Pubitemid 43237701)
31. Holtrich U, Wolf G, Brauninger A et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994;91:1736-1740. (Pubitemid 24080280)
32. Wolf G, Hildenbrand R, Schwar C et al. Polo-like kinase: A novel marker of proliferation: Correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196:753-759.
33. Tokumitsu Y, Mori M, Tanaka S et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999;15:687-692.
34. Knecht R, Elez R, Oechler M et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:2794-2797. (Pubitemid 29283110)
35. Ando K, Ozaki T, Yamamoto H et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-25561. (Pubitemid 38756815)
36. Wikman H, Kettunen E, Seppanen JK et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002;21:5804-5813. (Pubitemid 35333015)
37. Cogswell JP, Brown CE, Bisi JE et al. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000;11:615-623. (Pubitemid 32042984)
38. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-2108. (Pubitemid 43346913)
39. Renner AG, Dos Santos C, Recher C et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009;114:659-662.
40. Grinshtein N, Datti A, Fujitani M et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385-1395.
41. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-322. (Pubitemid 46241881)
42. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-5794. (Pubitemid 36576886)
43. Lenart P, Petronczki M, Steegmaier M et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315.
44. Paugh BS, Qu C, Jones C et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28:3061-3068.
45. Lee Y, Scheck AC, Cloughesy TF et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008;1:52.
46. The Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
47. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.
48. Lusa L, McShane LM, Reid JF et al. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst 2007;99:1715-1723. (Pubitemid 351767219)
49. Perou CM, Parker JS, Prat A et al. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010;11:718-719; author reply 20-21.
50. Wakimoto H, Kesari S, Farrell CJ et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69:3472-3481.
51. Pandita A, Aldape KD, Zadeh G et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36. (Pubitemid 37475250)
52. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-765. (Pubitemid 44949605)
53. Lenkiewicz M, Li N, Singh SK. Culture and isolation of brain tumor initiating cells. Curr Protoc Stem Cell Biol 2009;Chapter 3:Unit3.
54. Lee C, Dhillon J, Wang MY et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 2008;68: 8661-8666.
55. Verreault M, Strutt D, Masin D et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine. BMC Cancer 2011;11:124.
56. Trent J, Meltzer P, Rosenblum M et al. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci USA 1986;83:470-473. (Pubitemid 16080035)
57. Komitova M, Eriksson PS. Sox-2 is expressed by neural progenitors and astroglia in the adult rat brain. Neurosci Lett 2004;369:24-27. (Pubitemid 39369496)
58. Brazel CY, Limke TL, Osborne JK et al. Sox2 expression defines a heterogeneous population of neurosphere-forming cells in the adult murine brain. Aging Cell 2005;4:197-207. (Pubitemid 41602741)
59. Fukuda S, Kato F, Tozuka Y et al. Two distinct subpopulations of nestin-positive cells in adult mouse dentate gyrus. J Neurosci 2003;23: 9357-9366. (Pubitemid 37323035)
60. Gage FH. Neurogenesis in the adult brain. J Neurosci 2002;22:612-613. (Pubitemid 34141738)
61. Kaneko Y, Sakakibara S, Imai T et al. Musashi1: An evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci 2000;22:139-153. (Pubitemid 30098914)
62. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-570.
63. Gubbay J, Collignon J, Koopman P et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346: 245-250.
64. Wood HB, Episkopou V. Comparative expression of the mouse Sox1, Sox2 And Sox3 genes from pre-gastrulation to early somite stages. Mech Dev 1999;86:197-201. (Pubitemid 29371760)
65. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev 1997;7:338-344. (Pubitemid 27292285)
66. Bylund M, Andersson E, Novitch BG et al. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003;6:1162-1168. (Pubitemid 37346036)
67. Graham V, Khudyakov J, Ellis P et al. SOX2 functions to maintain neural progenitor identity. Neuron 2003;39:749-765. (Pubitemid 37088088)
68. Alonso MM, Diez-Valle R, Manterola L et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 2011;6:e26740.
69. Sun H, Zhang S. Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. Biochem Biophys Res Commun 2011;410:692-697.
70. Annovazzi L, Mellai M, Caldera V et al. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics 2011;8:139-147.
71. Schmitz M, Temme A, Senner V et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007;96:1293-1301. (Pubitemid 46625072)
72. Ikushima H, Todo T, Ino Y et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4. J Biol Chem 2011;286:41434-41441.
73. Gangemi RM, Griffero F, Marubbi D et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009;27:40-48.
74. Mross K, Frost A, Steinbild S et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26: 5511-5517.
75. Hofheinz RD, Al-Batran SE, Hochhaus A et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, Bi 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16:4666-4674.
76. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-841.
77. Olmos D, Barker D, Sharma R et al. Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies. Clin Cancer Res 2011;17:3420-3430.
78. Jimeno A, Li J, Messersmith WA et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-5510.
79. Hari M, Loganzo F, Annable T et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-278.
80. Greenberger LM, Lothstein L, Williams SS et al. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 1988;85:3762-3766.
81. Lee J, Son MJ, Woolard K et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80. (Pubitemid 350309742)
82. Barone G, Maurizi P, Tamburrini G et al. Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 2006;22:652-661. (Pubitemid 43933685)
83. Bartels U, Baruchel S, Carret AS et al. The use and effectiveness of temozolomide in children with central nervous system tumours: A survey from the Canadian Paediatric Brain Tumour Consortium. Curr Oncol 2011;18:e19-e24.
84. Lashford LS, Thiesse P, Jouvet A et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684-4691. (Pubitemid 36025286)
85. Dirks PB. Cancer: Stem cells and brain tumours. Nature 2006;444: 687-688. (Pubitemid 44949580)
86. Kanai R, Wakimoto H, Martuza RL et al. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011;17:3686-3696.
87. Cheema TA, Kanai R, Kim GW et al. Enhanced antitumor efficacy of low dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 2011;17: 7383-7393.